Trump to nominate CEA Chair Miran for Fed governor role
Investing.com -- The European Commission has granted Bristol Myers (NYSE:BMY) Squibb, the biopharmaceutical company based in Princeton, N.J., an expanded approval for its CAR-T cell therapy Breyanzi, according to the company on Friday.
The approval now extends to the use of Breyanzi in treating adults suffering from follicular lymphoma that has relapsed or proven to be refractory, and who have undergone two or more previous lines of systemic therapy.
Bristol Myers Squibb’s Breyanzi is a form of CAR-T cell therapy, a type of treatment that uses genetically modified cells from the patient’s immune system to fight cancer.
The expanded approval by the European Commission is a significant step for the biopharmaceutical company, as it allows for the wider use of Breyanzi in treating follicular lymphoma, a type of blood cancer.
The approval comes after the company demonstrated the effectiveness of Breyanzi in treating adults with this type of lymphoma who have not responded to other treatments or whose cancer has returned after treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.